ATE503498T1 - Pegylierte glykoformen von faktor vii - Google Patents
Pegylierte glykoformen von faktor viiInfo
- Publication number
- ATE503498T1 ATE503498T1 AT03729912T AT03729912T ATE503498T1 AT E503498 T1 ATE503498 T1 AT E503498T1 AT 03729912 T AT03729912 T AT 03729912T AT 03729912 T AT03729912 T AT 03729912T AT E503498 T1 ATE503498 T1 AT E503498T1
- Authority
- AT
- Austria
- Prior art keywords
- factor vii
- glycoforms
- pegylated
- polypeptides
- linked
- Prior art date
Links
- 229940012413 factor vii Drugs 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102100023804 Coagulation factor VII Human genes 0.000 abstract 2
- 108010023321 Factor VII Proteins 0.000 abstract 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- 150000002482 oligosaccharides Polymers 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 235000009582 asparagine Nutrition 0.000 abstract 1
- 229920001281 polyalkylene Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200200964 | 2002-06-21 | ||
| US39477802P | 2002-07-01 | 2002-07-01 | |
| PCT/DK2003/000420 WO2004000366A1 (en) | 2002-06-21 | 2003-06-20 | Pegylated factor vii glycoforms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE503498T1 true ATE503498T1 (de) | 2011-04-15 |
Family
ID=44256861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03729912T ATE503498T1 (de) | 2002-06-21 | 2003-06-20 | Pegylierte glykoformen von faktor vii |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1517710B1 (de) |
| JP (1) | JP4634145B2 (de) |
| KR (1) | KR101186140B1 (de) |
| CN (2) | CN1671420A (de) |
| AT (1) | ATE503498T1 (de) |
| AU (1) | AU2003240439B2 (de) |
| BR (1) | BR0311978A (de) |
| CA (1) | CA2490360A1 (de) |
| DK (1) | DK1517710T3 (de) |
| ES (1) | ES2363205T3 (de) |
| PL (1) | PL211175B1 (de) |
| PT (1) | PT1517710E (de) |
| RU (1) | RU2362807C2 (de) |
| UA (1) | UA86744C2 (de) |
| WO (1) | WO2004000366A1 (de) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7786070B2 (en) | 1997-09-10 | 2010-08-31 | Novo Nordisk Healthcare A/G | Subcutaneous administration of coagulation factor VII |
| ES2411007T3 (es) * | 2001-10-10 | 2013-07-04 | Novo Nordisk A/S | Remodelación y glicoconjugación de péptidos |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| NZ542094A (en) | 2003-03-14 | 2008-12-24 | Neose Technologies Inc | Branched polymer conjugates comprising a peptide and water-soluble polymer chains |
| US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
| PL1615945T3 (pl) | 2003-04-09 | 2012-03-30 | Ratiopharm Gmbh | Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami |
| US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| NZ548123A (en) | 2004-01-08 | 2010-05-28 | Novo Nordisk As | O-linked glycosylation of peptides |
| ES2642214T3 (es) * | 2004-01-21 | 2017-11-15 | Novo Nordisk Health Care Ag | Conjugación de péptidos mediante transglutaminasa |
| KR20070008645A (ko) | 2004-05-04 | 2007-01-17 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 폴리펩티드의 ｏ-연결된 단백당형 및 그들의 제조 방법 |
| EP1761630A2 (de) * | 2004-06-21 | 2007-03-14 | Novo Nordisk Health Care AG | Faktor-vii-varianten mit unterbrochener glykosylierung |
| US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
| WO2006031811A2 (en) | 2004-09-10 | 2006-03-23 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
| EP1797192A1 (de) * | 2004-09-29 | 2007-06-20 | Novo Nordisk Health Care AG | Modifizierte proteine |
| WO2006050247A2 (en) | 2004-10-29 | 2006-05-11 | Neose Technologies, Inc. | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
| JP2008526864A (ja) * | 2005-01-06 | 2008-07-24 | ネオス テクノロジーズ インコーポレイテッド | 糖断片を用いる糖結合 |
| US9029331B2 (en) | 2005-01-10 | 2015-05-12 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| WO2006121569A2 (en) | 2005-04-08 | 2006-11-16 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| EP2975135A1 (de) | 2005-05-25 | 2016-01-20 | Novo Nordisk A/S | Glykopegylierter Faktor IX |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| US8293708B2 (en) | 2005-08-30 | 2012-10-23 | Novo Nordisk Health Care A/G | Liquid formulations N-terminal serine of pegylated growth hormone |
| WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
| JP5280001B2 (ja) * | 2005-12-08 | 2013-09-04 | 株式会社カネカ | 外来性遺伝子由来のタンパク質がＧｌａ残基を含むトランスジェニック鳥類及びその作製法 |
| WO2007066775A1 (ja) * | 2005-12-08 | 2007-06-14 | Kaneka Corporation | 外来性遺伝子由来のタンパク質がＧｌａ残基を含むトランスジェニック鳥類及びその作製法 |
| MX2008014520A (es) * | 2006-05-22 | 2008-11-27 | Elan Pharm Inc | Preparacion de conjugados polimericos de compuestos terapeuticos, agricolas, y de aditivos para alimentos. |
| BRPI0713963A2 (pt) | 2006-07-07 | 2012-11-27 | Novo Nordisk Healthcare Ag | conjugados de proteìna e métodos para sua preparação |
| EP2049144B8 (de) | 2006-07-21 | 2015-02-18 | ratiopharm GmbH | Glycosylierung von peptiden über o-verbundene glycosylierungssequenzen |
| FR2904558B1 (fr) * | 2006-08-01 | 2008-10-17 | Lab Francais Du Fractionnement | "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees" |
| CN101535339B (zh) * | 2006-09-01 | 2014-11-12 | 诺沃-诺迪斯克保健股份有限公司 | 改性糖蛋白 |
| WO2008025856A2 (en) * | 2006-09-01 | 2008-03-06 | Novo Nordisk Health Care Ag | Modified glycoproteins |
| EP2054521A4 (de) | 2006-10-03 | 2012-12-19 | Novo Nordisk As | Verfahren zur reinigung von polypeptid-konjugate |
| ES2655734T3 (es) * | 2006-10-04 | 2018-02-21 | Novo Nordisk A/S | Glicopéptidos y azúcares pegilados unidos a glicerol |
| PT2101821E (pt) * | 2006-12-15 | 2014-10-03 | Baxter Int | Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo |
| US20100143326A1 (en) * | 2007-01-03 | 2010-06-10 | Novo Nordisk Healthcare A/G | SUBCUTANEOUS ADMINISTRATION OF COAGULATION FACTOR VIIa-RELATED POLYPEPTIDES |
| HRP20130382T1 (hr) | 2007-04-03 | 2013-05-31 | Biogenerix Ag | Postupci lijeäśenja pomoä†u glikopegiliranog g-csf |
| CN104887620A (zh) | 2007-05-02 | 2015-09-09 | 诺沃—诺迪斯克保健股份有限公司 | 包括芳香族防腐剂和抗氧化剂的高浓度因子vii多肽制剂 |
| CA2690611C (en) | 2007-06-12 | 2015-12-08 | Novo Nordisk A/S | Improved process for the production of nucleotide sugars |
| EP2014299A1 (de) * | 2007-07-11 | 2009-01-14 | Novo Nordisk A/S | Subkutane Verabreichung des Gerinnungsfaktors VII |
| US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
| US11197916B2 (en) | 2007-12-28 | 2021-12-14 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
| SG187410A1 (en) | 2007-12-28 | 2013-02-28 | Baxter Int | Recombinant vwf formulations |
| PL2257311T3 (pl) | 2008-02-27 | 2014-09-30 | Novo Nordisk As | Koniugaty cząsteczek czynnika VIII |
| TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子ｖｉｉ多肽和其用途 |
| WO2009141418A1 (en) * | 2008-05-23 | 2009-11-26 | Novo Nordisk A/S | Formulations of peg-functionalised serine proteases with high concentrations of an aromatic preservative |
| US20100099616A1 (en) * | 2008-10-17 | 2010-04-22 | Baxter International Inc. | Modified blood factors comprising a low degree of water soluble polymer |
| EP2349314B1 (de) | 2008-10-21 | 2013-02-27 | Baxter International Inc. | Lyophilisierte rekombinante vwf-formulierungen |
| US9241896B2 (en) | 2008-12-19 | 2016-01-26 | Ultragenyx Pharmaceutical Inc. | Methods and formulations for treating sialic acid deficiencies |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| EP3093029A1 (de) | 2009-07-27 | 2016-11-16 | Baxalta GmbH | Koagulationsproteinkonjugate |
| ES2597954T3 (es) | 2009-07-27 | 2017-01-24 | Baxalta GmbH | Conjugados de proteína de la coagulación sanguínea |
| JP5909755B2 (ja) | 2009-07-27 | 2016-04-27 | リポクセン テクノロジーズ リミテッド | 非血液凝固タンパク質の糖ポリシアル酸化 |
| CN102812039B (zh) | 2010-02-16 | 2016-01-20 | 诺沃—诺迪斯克有限公司 | 缀合蛋白质 |
| GB201007356D0 (en) * | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
| KR20140003380A (ko) * | 2010-07-13 | 2014-01-09 | 울트라제닉스 파마수티컬 인코포레이티드 | 시알산 결함 치료용 방법들 및 제형들 |
| EP2957628A1 (de) | 2010-10-05 | 2015-12-23 | Novo Nordisk Health Care AG | Verfahren zur proteinherstellung |
| BR112013015898A2 (pt) | 2010-12-22 | 2018-06-26 | Baxter International Inc. | derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada. |
| HK1201067A1 (en) | 2011-10-24 | 2015-08-21 | 罕见病药物研发公司 | Sialic acid analogs |
| MY190257A (en) | 2012-04-16 | 2022-04-11 | Cantab Biopharmaceuticals Patents Ltd | Optimised subcutaneous therapeutic agents |
| US10385085B2 (en) | 2015-09-14 | 2019-08-20 | Ultragenyx Pharmaceutical Inc. | Crystal forms of sialic acid or salt or solvate thereof |
| EP3833381B1 (de) | 2019-08-15 | 2022-08-03 | Catalyst Biosciences, Inc. | Modifizierte faktor-vii-polypeptide zur subkutanen verabreichung |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4456591A (en) | 1981-06-25 | 1984-06-26 | Baxter Travenol Laboratories, Inc. | Therapeutic method for activating factor VII |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| GB8430252D0 (en) | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
| GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| JP2524586B2 (ja) | 1985-06-26 | 1996-08-14 | シタス コーポレイション | ポリマ−接合を利用する医薬組成物用蛋白質の可溶化 |
| US4975282A (en) | 1985-06-26 | 1990-12-04 | The Liposome Company, Inc. | Multilamellar liposomes having improved trapping efficiencies |
| US5272066A (en) | 1986-03-07 | 1993-12-21 | Massachusetts Institute Of Technology | Synthetic method for enhancing glycoprotein stability |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4847325A (en) | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
| GB8824591D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| ES2136595T5 (es) | 1989-04-19 | 2004-04-01 | Enzon, Inc. | Carbonatos activos de oxidos de polialquileno para la modificacion de polipeptidos. |
| US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| DK0400472T3 (da) | 1989-05-27 | 1996-05-13 | Sumitomo Pharma | Fremgangsmåde til fremstilling af polyethylenglycolderivater og modificeret protein |
| US5580560A (en) | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
| US5219564A (en) | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
| EP0513332A4 (en) | 1990-11-14 | 1993-03-17 | Cargill, Incorporated | Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins |
| US5997864A (en) | 1995-06-07 | 1999-12-07 | Novo Nordisk A/S | Modified factor VII |
| JPH06506217A (ja) | 1991-03-18 | 1994-07-14 | エンゾン，インコーポレーテッド | ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体 |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US5212075A (en) | 1991-04-15 | 1993-05-18 | The Regents Of The University Of California | Compositions and methods for introducing effectors to pathogens and cells |
| US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
| ZA933926B (en) | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
| AU5006993A (en) | 1992-08-21 | 1994-03-15 | Enzon, Inc. | Novel attachment of polyalkylene oxides to bio-effecting substances |
| US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| NZ250375A (en) | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
| US5298643A (en) | 1992-12-22 | 1994-03-29 | Enzon, Inc. | Aryl imidate activated polyalkylene oxides |
| US5349001A (en) | 1993-01-19 | 1994-09-20 | Enzon, Inc. | Cyclic imide thione activated polyalkylene oxides |
| US5321095A (en) | 1993-02-02 | 1994-06-14 | Enzon, Inc. | Azlactone activated polyalkylene oxides |
| IL104734A0 (en) | 1993-02-15 | 1993-06-10 | Univ Bar Ilan | Bioactive conjugates of cellulose with amino compounds |
| US5374541A (en) | 1993-05-04 | 1994-12-20 | The Scripps Research Institute | Combined use of β-galactosidase and sialyltransferase coupled with in situ regeneration of CMP-sialic acid for one pot synthesis of oligosaccharides |
| WO1994028024A1 (en) | 1993-06-01 | 1994-12-08 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
| AU7113594A (en) | 1993-06-21 | 1995-01-17 | Enzon, Inc. | Site specific synthesis of conjugated peptides |
| GB9317618D0 (en) | 1993-08-24 | 1993-10-06 | Royal Free Hosp School Med | Polymer modifications |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| ATE214940T1 (de) | 1993-11-10 | 2002-04-15 | Enzon Inc | Verbesserte interferon-polymerkonjugate |
| US5446090A (en) * | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5473034A (en) | 1994-03-18 | 1995-12-05 | Hyogo Prefectural Government | Method for producing protein-synthetic polymer conjugate and said conjugate produced thereby |
| US5629384A (en) | 1994-05-17 | 1997-05-13 | Consiglio Nazionale Delle Ricerche | Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces |
| AU2826495A (en) | 1994-06-02 | 1996-01-04 | Enzon, Inc. | Method of solubilizing substantially water insoluble materials |
| US5730990A (en) | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
| US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
| CA2204726A1 (en) | 1994-11-09 | 1996-12-27 | Robin E. Offord | Functionalized polymers for site-specific attachment |
| US5738846A (en) | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| WO1996040791A1 (en) | 1995-06-07 | 1996-12-19 | Novo Nordisk A/S | Modification of polypeptides |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| US5747639A (en) | 1996-03-06 | 1998-05-05 | Amgen Boulder Inc. | Use of hydrophobic interaction chromatography to purify polyethylene glycols |
| TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| EP0964702B1 (de) | 1996-08-02 | 2006-10-04 | Ortho-McNeil Pharmaceutical, Inc. | Polypeptide mit einzelnem kovalent gebundenen n-terminalen wasserlöslichen polymer |
| JP2001507215A (ja) | 1997-01-16 | 2001-06-05 | サイテル コーポレイション | 組換え糖タンパク質のインビトロでの実用的なシアリル化 |
| WO1998032466A1 (en) | 1997-01-29 | 1998-07-30 | Polymasc Pharmaceuticals Plc | Pegylation process |
| EP0979102A4 (de) | 1997-04-30 | 2005-11-23 | Enzon Inc | Einzelsträngige polypeptide modifiziert durch polyalkylenoxid |
| JP4011124B2 (ja) | 1997-06-06 | 2007-11-21 | 協和醗酵工業株式会社 | 化学修飾ポリペプチド |
| US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
| US5981709A (en) | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
| CA2739933A1 (en) * | 2000-02-11 | 2001-08-16 | Bayer Healthcare Llc | Factor vii or viia-like molecules |
| JP4455802B2 (ja) | 2000-05-03 | 2010-04-21 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | ヒト第ｖｉｉ凝固因子変異型 |
| US6423826B1 (en) * | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
| WO2002022776A2 (en) | 2000-09-13 | 2002-03-21 | Novo Nordisk A/S | Human coagulation factor vii variants |
| BR0114373A (pt) * | 2000-10-02 | 2004-02-17 | Novo Nordisk As | Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante |
| CZ20032454A3 (en) | 2001-03-22 | 2004-03-17 | Novo Nordisk Health Care Ag | Coagulation factor vii derivative |
| CZ2004427A3 (cs) | 2001-09-27 | 2004-08-18 | Novoánordiskáhealthácareáag | Polypeptidy lidského koagulačního faktoru VII |
| JP2005512524A (ja) | 2001-11-02 | 2005-05-12 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | ヒト凝固第ｖｉｉ因子ポリペプチド |
-
2003
- 2003-06-20 UA UA20041210113A patent/UA86744C2/ru unknown
- 2003-06-20 BR BR0311978-5A patent/BR0311978A/pt not_active IP Right Cessation
- 2003-06-20 EP EP03729912A patent/EP1517710B1/de not_active Revoked
- 2003-06-20 ES ES03729912T patent/ES2363205T3/es not_active Expired - Lifetime
- 2003-06-20 AT AT03729912T patent/ATE503498T1/de active
- 2003-06-20 CN CNA038174170A patent/CN1671420A/zh active Pending
- 2003-06-20 KR KR1020047020875A patent/KR101186140B1/ko not_active Expired - Fee Related
- 2003-06-20 CN CN2008100094681A patent/CN101301475B/zh not_active Expired - Fee Related
- 2003-06-20 RU RU2005101348/13A patent/RU2362807C2/ru not_active IP Right Cessation
- 2003-06-20 DK DK03729912.0T patent/DK1517710T3/da active
- 2003-06-20 JP JP2004530894A patent/JP4634145B2/ja not_active Expired - Fee Related
- 2003-06-20 AU AU2003240439A patent/AU2003240439B2/en not_active Ceased
- 2003-06-20 PL PL374318A patent/PL211175B1/pl not_active IP Right Cessation
- 2003-06-20 WO PCT/DK2003/000420 patent/WO2004000366A1/en not_active Ceased
- 2003-06-20 CA CA002490360A patent/CA2490360A1/en not_active Abandoned
- 2003-06-20 PT PT03729912T patent/PT1517710E/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2490360A1 (en) | 2003-12-31 |
| JP4634145B2 (ja) | 2011-02-16 |
| AU2003240439A1 (en) | 2004-01-06 |
| BR0311978A (pt) | 2005-03-22 |
| EP1517710B1 (de) | 2011-03-30 |
| AU2003240439B2 (en) | 2009-05-21 |
| CN101301475A (zh) | 2008-11-12 |
| PL211175B1 (pl) | 2012-04-30 |
| KR101186140B1 (ko) | 2012-09-27 |
| CN1671420A (zh) | 2005-09-21 |
| ES2363205T3 (es) | 2011-07-26 |
| RU2362807C2 (ru) | 2009-07-27 |
| PL374318A1 (en) | 2005-10-17 |
| WO2004000366A1 (en) | 2003-12-31 |
| PT1517710E (pt) | 2011-07-08 |
| DK1517710T3 (da) | 2011-07-18 |
| CN101301475B (zh) | 2012-12-19 |
| JP2006513142A (ja) | 2006-04-20 |
| RU2005101348A (ru) | 2005-08-27 |
| KR20050016612A (ko) | 2005-02-21 |
| EP1517710A1 (de) | 2005-03-30 |
| UA86744C2 (en) | 2009-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE503498T1 (de) | Pegylierte glykoformen von faktor vii | |
| NO20050324L (no) | Pegylerte faktor-VII-glykoformer | |
| ATE203396T1 (de) | Spritzgegossene darreichungsform | |
| DE69812946D1 (de) | Ethylenpolymerzusammensetzungen und daraus hergestellte gegenstände | |
| DK1539101T3 (da) | Injicerbare, multi-modale polymere depotsammens tninger og anvendelser deraf | |
| DE60215554D1 (de) | Ionenleitende membran mit hoher härte und dimensionalstabilität | |
| WO2004043474A3 (de) | Verwendung eines oder mehrerer der elemente aus der gruppe yttrium, neodym und zirconium | |
| DE69928938D1 (de) | Neues cyclosporin mit verbesserter wirkung | |
| AU4012100A (en) | Pseudotyped lentiviral vectors and uses thereof | |
| HUP0103265A3 (en) | Cyclic prosaposin-derived peptides, pharmaceutical compositions comprising thereof and their use | |
| ZA200204603B (en) | Amphiphilic polymers and polypeptide conjugates comprising same. | |
| DE50008510D1 (de) | Niedermolekulare inhibitoren von komplementproteasen | |
| EP1988099A3 (de) | Insektizide Proteine von Bacillus thuringiensis | |
| AU8738401A (en) | Novel kallikrein gene | |
| EP1800629A3 (de) | Polymerstent mit veränderten Molekülstrukturen in den flexiblen Verbindungen und in den Radialbögen der Ringe | |
| WO2003048205A3 (fr) | Proteines a activite inhibitrice de l'il-6 | |
| WO2004076474A3 (en) | Polyethylene glycol modified interferon compositions and methods of use thereof | |
| FR2809624B1 (fr) | Utilisation comme substitut sanguin d'une hemoglobine extracellulaire de poids moleculaire eleve | |
| WO2002062856A3 (de) | Mikroverkapselte biologisch aktive wirkstoffe enthaltend ein wasserlösliches oder wasserdispergierbares kammpolymer | |
| TR200003007A3 (tr) | Halat saptirimi ve uygun sentetik elyaftan halat ve bunlarin kullanimi. | |
| BR0009325B1 (pt) | composições moldadas de policarbonato modificadas por polìmero de enxerto, uso das mesmas e corpos moldados. | |
| HUP0201696A3 (en) | Cyclic peptides, pharmaceutical compositions comprising thereof and their use | |
| EP1790655A3 (de) | Biologisch aktive Peptide | |
| ATE426643T1 (de) | Pigmentzubereitung | |
| FR2828687B1 (fr) | Nouveaux peptides et leur utilisation comme medicaments contre l'infection par le fiv chez le chat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1517710 Country of ref document: EP |